Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

• Published in: Clinical cancer research Vol. 14; no. 11; pp. 3268 - 3277
• Main Authors: SHOEMAKER, Alex R, MITTEN, Michael J, BAUCH, Joy, MARSH, Kennan, TAHIR, Steven K, XIUFENYANG, TSE, Christin, FESIK, Stephen W, ROSENBERG, Saul H, ELMORE, Steven W, ADICKES, Jessica, ACKLER, Scott, REFICI, Marion, FERGUSON, Debra, OLEKSIJEW, Anatol, O'CONNOR, Jacqueline M, BAOLE WANG, FROST, David J
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.06.2008
• Subjects: ABT-263; Aniline Compounds - administration & dosage; Animals; Antineoplastic agents; Antineoplastic Agents - administration & dosage; apoptosis; Bcl-2; Biological and medical sciences; Carcinoma, Small Cell - drug therapy; Dose-Response Relationship, Drug; Humans; Lung Neoplasms - drug therapy; Medical sciences; Mice; Mice, Nude; Pharmacology. Drug treatments; Pneumology; Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors; Proto-Oncogene Proteins c-bcl-2 - drug effects; small cell lung cancer; Sulfonamides - administration & dosage; Tumors of the respiratory system and mediastinum; xenograft; Xenograft Model Antitumor Assays; Lung disease; Respiratory disease; Animal; Lung cancer; Bonchopulmonary small cell carcinoma; C-Onc gene; Bronchus disease; Inhibitor; Malignant tumor; Biological activity; Protooncogene; Cancer
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-07-4622

Purpose: The purpose of this study was to characterize the activity of the Bcl-2 protein family inhibitor ABT-263 in a panel of small cell lung cancer (SCLC) xenograft models. Experimental Design: A panel of 11 SCLC xenograft models was established to evaluate the efficacy of ABT-263. Single agent activity was examined on a continuous dosing schedule in each of these models. The H146 model was used to further evaluate dose and schedule, comparison to standard cytotoxic agents, and induction of apoptosis. Results: ABT-263 exhibited a range of antitumor activity, leading to complete tumor regression in several models. Significant regressions of tumors as large as 1 cc were also observed. The efficacy of ABT-263 was also quite durable; in several cases, minimal tumor regrowth was noted several weeks after the cessation of treatment. Antitumor effects were equal or superior to that of several clinically approved cytotoxic agents. Regression of large established tumors was observed through several cycles of therapy and efficacy was retained in a Pgp-1 overexpressing line. Significant efficacy was observed on several dose and therapeutic schedules and was associated with significant induction of apoptosis. Conclusions: ABT-263 is a potent, orally bioavailable inhibitor of Bcl-2 family proteins that has recently entered clinical trials. The efficacy data reported here suggest that SCLC is a promising area of clinical investigation with this agent.